Business · 22/04/2015Updated: 10/17/2026 · 1 min read

FDA Releases Guidance for Clinical Trial Endpoints in Non-Small Cell Lung Cancer Drug Approvals

The FDA has finalized a guidance document outlining recommended endpoints for clinical trials of non-small cell lung cancer drugs and biologics to support effectiveness claims in new drug applications and other FDA submissions.